These findings provide mechanistic insight in which AGE-activated MD2-TLR4 orchestrates adverse cardiac tissue remodeling in diabetes, and underscore MD2 as a potential target for DCM. This evidence concerns the gene LY96 and familial dilated cardiomyopathy.